You are here: Welcome to the MPKB » Welcome to the MPKB » Publications & presentations » Presentation - The human microbiome is the mechanism fueling neurodegenerative disorders
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:publications:marshall_neurotalk2011 [07.15.2011] – [Transcript] jrfoutinhome:publications:marshall_neurotalk2011 [07.15.2011] – [Transcript] jrfoutin
Line 23: Line 23:
 Now our next speaker is Trevor Marshall and he is currently in the United States, the Director of Autoimmunity Research in Thousand Oaks in California. Since he is an Australian, he also keeps one foot in the door in Australia and he is adjunct professor in the faculty of Health Sciences at Murdock University, and that is in Western Australia. And I think he just went from the South to the West.\\ Now our next speaker is Trevor Marshall and he is currently in the United States, the Director of Autoimmunity Research in Thousand Oaks in California. Since he is an Australian, he also keeps one foot in the door in Australia and he is adjunct professor in the faculty of Health Sciences at Murdock University, and that is in Western Australia. And I think he just went from the South to the West.\\
  
-TM: Right, but we are still in the antipathy, so to that is something. But most of my work now is based in California with the Autoimmunity Research Foundation. \\+**TM:** Right, but we are still in the antipathy, so to that is something. But most of my work now is based in California with the Autoimmunity Research Foundation. \\
  
 **00:51\\ **00:51\\
Line 74: Line 74:
  
 Quite an amazing case history, but it is //not// just Multiple Sclerosis.\\ Quite an amazing case history, but it is //not// just Multiple Sclerosis.\\
- 
  
 **07:56\\ **07:56\\
Line 144: Line 143:
 What you probably can not see from the back is if you look at the GFR, the GFR started at 70, which is not really good, and it started at about 70 and by about three years it had dropped down to 40 and it has maintained stably at about 40 for the subsequent three or four years of therapy.\\ What you probably can not see from the back is if you look at the GFR, the GFR started at 70, which is not really good, and it started at about 70 and by about three years it had dropped down to 40 and it has maintained stably at about 40 for the subsequent three or four years of therapy.\\
    
-When you have a patient with a GFR of 40, you would normally be pressing the panic buttons, but when you are changing the paradigm of the therapy that you are using, the panic buttons change. It is a very difficult problem that we have to solve.\\+When you have a patient with a GFR of 40, you would normally be pressing the panic buttons, but **when you are changing the paradigm of the therapy that you are using, the panic buttons change.** It is a very difficult problem that we have to solve.\\ 
 + 
 +<blockquote> **"//When you are changing the paradigm of the therapy that you are using, the panic buttons change."//** </blockquote>
      
 **15:45**\\ **15:45**\\
Line 203: Line 204:
  
 **21:06**\\ **21:06**\\
-**Mycobacterium tuberculosis**\\+**//Mycobacterium tuberculosis//**\\
  
 Also, Mycobacterium tuberculosis; some very good work done here in China, in 2003, which showed that the VDR receptor was downregulated when a cell was infected with Mycobacterium tuberculosis.\\ Also, Mycobacterium tuberculosis; some very good work done here in China, in 2003, which showed that the VDR receptor was downregulated when a cell was infected with Mycobacterium tuberculosis.\\
Line 235: Line 236:
 But we are still accumulating from long-term recovery data in Multiple Sclerosis, Schizophrenia, OCD, Dementia, Multiple System Atrophy, Amyotrophic Lateral Sclerosis, but all in very low numbers at this point.\\ But we are still accumulating from long-term recovery data in Multiple Sclerosis, Schizophrenia, OCD, Dementia, Multiple System Atrophy, Amyotrophic Lateral Sclerosis, but all in very low numbers at this point.\\
  
-The other thought I want to leave you with which is the thought that the previous speaker had, which is, that by the time the brain becomes infected, many systemic pathways are also already active, and vice versa, by the time systemic disease becomes manifest, the brain is very often affected, with a few exceptions, like ALS, which I am obviously intrigued with.\\+The other thought I want to leave you with which is the thought that the previous speaker had, which is, that **by the time the brain becomes infected, many systemic pathways are also already active, and vice versa, by the time systemic disease becomes manifest, the brain is very often affected, with a few exceptions,** like ALS, which I am obviously intrigued with.\\
  
-As we move to the future, there really has to be a choice made, by the physician or by the patient, for immunosuppression to give short term productivity/long term relapse and immobility—and immunostimulation to give short term inability and the long term productivity.\\+As we move to the future, **there really has to be a choice made, by the physician or by the patient, for immunosuppression to give short term productivity/long term relapse and immobility—and immunostimulation to give short term inability and the long term productivity.**\\
  
 **25:29**\\ **25:29**\\
Line 255: Line 256:
 **Q1:** Well, thanks. There is something on my mind that I would like to start. What do we look for? Like you say, these bugs, we are looking within the cells so there is not so much external. Normal septic person apparently as I understand it. So what, how can we test for this purpose?\\ **Q1:** Well, thanks. There is something on my mind that I would like to start. What do we look for? Like you say, these bugs, we are looking within the cells so there is not so much external. Normal septic person apparently as I understand it. So what, how can we test for this purpose?\\
  
-**TM:** It is even more complex than that. That optical microscopy that I showed you, what we do there is we put blood between two cover slips and then allow the blood to age. Between about six and thirty-six hours the cells that are infected start to explode like that. So you look at them after thirty-six hours and there is just debris, there are no signs of cells. So in typical sampling operations that one does in a clinical basis, you do not see this.\\+**TM:** It is even more complex than that. That optical microscopy that I showed you, what we do there is we put blood between two cover slips and then allow the blood to age. Between about six and thirty-six hours the cells that are infected start to explode like that. So you look at them after thirty-six hours and there is just debris, there are no signs of cells. So **in typical sampling operations that one does in a clinical basis, you do not see this.**\\
    
 **Q1:** Yes, you have access to a regular microscope slide so you can look at brain tissue? When you are looking at a Parkinson's brain, you can not see anything.\\ **Q1:** Yes, you have access to a regular microscope slide so you can look at brain tissue? When you are looking at a Parkinson's brain, you can not see anything.\\
Line 293: Line 294:
 **TM:** Very quickly. The body changes. The hormonal balance changes very quickly within two to three weeks.  **TM:** Very quickly. The body changes. The hormonal balance changes very quickly within two to three weeks. 
 If people are on thyroid medication, that has to be continuously modified, because usually within 18 months they are off thyroid medications. The whole balance changes very quickly with the immunopathology setting in and with the therapy.\\ If people are on thyroid medication, that has to be continuously modified, because usually within 18 months they are off thyroid medications. The whole balance changes very quickly with the immunopathology setting in and with the therapy.\\
 +
 +\\
      
  
- +----
- +
- +
- +
- +
  
  
 {{tag>presentations videos Trevor_Marshall_PhD 2011}} {{tag>presentations videos Trevor_Marshall_PhD 2011}}
  
home/publications/marshall_neurotalk2011.txt · Last modified: 07.04.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.